Corline Biomedical
10.3 SEK -1.44%Be the first to follow this company
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Revenue
25.03M
EBIT %
-7.15 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CLBIO
Daily low / high price
10.2 / 10.45
SEK
Market cap
221.36M SEK
Turnover
7.07K SEK
Volume
689
Financial calendar
General meeting
15.05.2024
Interim report
23.08.2024
Interim report
07.11.2024
Annual report
17.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Adam Dahlberg | 26.7 % | 26.7 % |
HealthInvest Microcap Fund AB | 9.9 % | 9.9 % |
Premium
This content is for our Premium customers only.